Effectiveness of Aspirin on Double Lumen Permanent Catheter Efficacy in ESRD

Authors Information
Article Notes and Dates
To Cite : Mozafar M, Samsami M, Sobhiyeh M R, Jabbehdari S, Fallah Zavareh M. et al. Effectiveness of Aspirin on Double Lumen Permanent Catheter Efficacy in ESRD, Nephro-Urol Mon. 2013 ;5(2):762-5. doi: 10.5812/numonthly.8733.
Abstract
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Hakim R, Himmelfarb J. Hemodialysis access failure: a call to action. Kidney Int. 1998; 54(4): 1029-40[DOI][PubMed]
  • 2. Windus DW. Permanent vascular access: a nephrologist's view. Am J Kidney Dis. 1993; 21(5): 457-71[PubMed]
  • 3. Smits JH, van der Linden J, Blankestijn PJ, Rabelink TJ. Coagulation and haemodialysis access thrombosis. Nephrol Dial Transplant. 2000; 15(11): 1755-60[PubMed]
  • 4. Bern MM, Lokich JJ, Wallach SR, Bothe A, Jr, Benotti PN, Arkin CF, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med. 1990; 112(6): 423-8[PubMed]
  • 5. Boraks P, Seale J, Price J, Bass G, Ethell M, Keeling D, et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol. 1998; 101(3): 483-6[PubMed]
  • 6. Obialo CI, Conner AC, Lebon LF. Maintaining patency of tunneled hemodialysis catheters--efficacy of aspirin compared to warfarin. Scand J Urol Nephrol. 2003; 37(2): 172-6[DOI][PubMed]
  • 7. Lee T, Lok C, Vazquez M, Moist L, Maya I, Mokrzycki M. Minimizing hemodialysis catheter dysfunction: an ounce of prevention. Int J Nephrol. 2012; 2012: 170857[DOI][PubMed]
  • 8. Haire WD, Lieberman RP, Lund GB, Edney JA, Kessinger A, Armitage JO. Thrombotic complications of silicone rubber catheters during autologous marrow and peripheral stem cell transplantation: prospective comparison of Hickman and Groshong catheters. Bone Marrow Transplant. 1991; 7(1): 57-9[PubMed]
  • 9. NKF-DOQI Clinical Practice Guidelines for Vascular Access.Guideline 23 treatment of tunneled cuffed catheter dysfunction. Am J Kidney Dis. 1997; 30-6
  • 10. Suhocki PV, Conlon PJ, Jr, Knelson MH, Harland R, Schwab SJ. Silastic cuffed catheters for hemodialysis vascular access: thrombolytic and mechanical correction of malfunction. Am J Kidney Dis. 1996; 28(3): 379-86[PubMed]
  • 11. Rysz J, Majewska E, Stolarek RA, Banach M, Cialkowska-Rysz A, Baj Z. Increased levels of soluble TNF-alpha receptors and cellular adhesion molecules in patients undergoing bioincompatible hemodialysis. Am J Nephrol. 2006; 26(5): 437-44[DOI][PubMed]
  • 12. Cox K, Vesely TM, Windus DW, Pilgram TK. The utility of brushing dysfunctional hemodialysis catheters. J Vasc Interv Radiol. 2000; 11(8): 979-83[PubMed]
  • 13. Weiss MF, Scivittaro V, Anderson JM. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis. 2001; 37(5): 970-80[PubMed]
  • 14. Grosser N, Schroder H. Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler Thromb Vasc Biol. 2003; 23(8): 1345-51[DOI][PubMed]
  • 15. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999; 100(8): 793-8[PubMed]
  • 16. Deguchi N, Ohigashi T, Tazaki H, Handa M, Ikeda Y. Haemodialysis and platelet activation. Nephrol Dial Transplant. 1991; 6 Suppl 2: 40-2[PubMed]
  • 17. Viener A, Aviram M, Better OS, Brook JG. Enhanced in vitro platelet aggregation in hemodialysis patients. Nephron. 1986; 43(2): 139-43[PubMed]
  • 18. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329): 71-86[PubMed]
  • 19. Reddan DN. Therapy for cardiovascular disease in patients with chronic kidney disease: appropriate caution or the absence of data. Am Heart J. 2002; 144(2): 206-7[PubMed]
  • 20. Liu JH, Lin PW, Liu YL, Lin HH, Huang CC. Comparison of classical and non-classical cardiovascular risk factors influencing the patency of native arteriovenous fistulas after percutaneous transluminal angioplasty therapy among haemodialysis patients. Postgrad Med J. 2007; 83(982): 547-51[DOI][PubMed]
  • 21. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol. 2009; 20(4): 872-81[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Nephro-Urology Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check